Bullous Pemphigoid (BP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Bullous Pemphigoid (BP) Market Outlook
Thelansis’s “Bullous Pemphigoid (BP)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Bullous Pemphigoid (BP) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Bullous
Pemphigoid (BP) Overview
Bullous
pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder,
representing 80% of subepidermal immunobullous cases. Bullous pemphigoid most
commonly affects elderly patients between the ages of 60 to 80 years. While the
clinical presentation of bullous pemphigoid is broad, the immunobullous skin
disorder characteristically presents with tense bullae and intense generalized
pruritus. In atypical cases, bullous lesions may be absent, and these cases
require a high degree of clinical suspicion. A biopsy for hematoxylin and eosin
staining will show a subepidermal split with eosinophils, and direct
immunofluorescence will highlight the autoantibodies against the basement
membrane zone. ELISA testing is also useful in diagnosing bullous pemphigoid.
Treatment depends on the severity of the disease; Current systemic treatment
options for bullous pemphigoid are limited to corticosteroids and
immunosuppressants, which can have substantial side effects on these vulnerable
patients that even exceed their therapeutic benefits.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment